Valuation: Phytopharm plc

Market Cap 1.8Cr 2.43Cr 2.12Cr 1.96Cr 3.41Cr 233.47Cr 3.47Cr 23Cr 9.17Cr 114.11Cr 9.11Cr 8.91Cr 393.32Cr P/E 2026 *
-5.89x
P/E 2027 * -6.35x
Enterprise Value 77.89L 1.05Cr 91.85L 84.73L 1.48Cr 101.09Cr 1.5Cr 10Cr 3.97Cr 49Cr 3.95Cr 3.86Cr 170.3Cr EV / Sales 2026 *
0.97x
EV / Sales 2027 * 1.32x
Free-Float
89.25%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 19/08/2024
Director of Finance/CFO 50 21/08/2019
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Chairman 51 -
Director/Board Member 62 05/10/2023
Director/Board Member 50 21/08/2019
Change 5-day change 1-year change 3-year change Capi.($)
-0.17%+1.47%+3.16%+6.80% 5.04TCr
-0.29%-2.81%+387.81%+591.82% 3.93TCr
-0.49%+1.48%+31.16%-6.46% 3.47TCr
+1.53%+3.11%+15.41%+58.54% 3.41TCr
+1.68%-0.62%+3.30%+27.34% 2.66TCr
+1.13%-3.11% - - 1.65TCr
-1.29%-0.52%+69.24%+117.60% 1.53TCr
+0.43%+3.34%+14.96%+17.46% 1.38TCr
+2.45%+3.99%+18.20%-30.12% 1.29TCr
Average +0.55%+0.92%+67.90%+97.87% 2.71TCr
Weighted average by Cap. +0.40%+0.79%+81.94%+122.30%

Financials

2026 *2027 *
Net sales 80L 1.08Cr 94.34L 87.03L 1.52Cr 103.83Cr 1.54Cr 10Cr 4.08Cr 51Cr 4.05Cr 3.96Cr 174.91Cr 90L 1.21Cr 1.06Cr 97.91L 1.71Cr 116.81Cr 1.73Cr 12Cr 4.59Cr 57Cr 4.56Cr 4.46Cr 196.78Cr
Net income -21.43L -28.9L -25.27L -23.31L -40.6L -28Cr -41.3L -2.78Cr -1.09Cr -14Cr -1.09Cr -1.06Cr -47Cr -28.01L -37.78L -33.03L -30.47L -53.07L -36Cr -53.98L -3.64Cr -1.43Cr -18Cr -1.42Cr -1.39Cr -61Cr
Net Debt -1.02Cr -1.38Cr -1.2Cr -1.11Cr -1.93Cr -132.38Cr -1.97Cr -13Cr -5.2Cr -65Cr -5.17Cr -5.05Cr -223.02Cr -61L -82.28L -71.93L -66.36L -1.16Cr -79Cr -1.18Cr -7.92Cr -3.11Cr -39Cr -3.09Cr -3.02Cr -133.37Cr
Logo Phytopharm plc
IXICO plc is engaged in neuroscience imaging and biomarker analytics, using its artificial intelligence (AI)-driven platform to help advance drug development in neurological disorders. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.
Employees
-
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-